Medulloblastoma, the most common malignant paediatric brain tumour, arises in the cerebellum and disseminates through the cerebrospinal fluid in the leptomeningeal space to coat the brain and spinal cord 1 . Dissemination, a marker of poor prognosis, is found in up to 40% of children at diagnosis and in most children at the time of recurrence. Affected children therefore are treated with radiation to the entire developing brain and spinal cord, followed by high-dose chemotherapy, with the ensuing deleterious effects on the developing nervous system 2 . The mechanisms of dissemination through the cerebrospinal fluid are poorly studied, and medulloblastoma metastases have been assumed to be biologically similar to the primary tumour 3,4 . Here we show that in both mouse and human medulloblastoma, the metastases from an individual are extremely similar to each other but are divergent from the matched primary tumour. Clonal genetic events in the metastases can be demonstrated in a restricted subclone of the primary tumour, suggesting that only rare cells within the primary tumour have the ability to metastasize. Failure to account for the bicompartmental nature of metastatic medulloblastoma could be a major barrier to the development of effective targeted therapies.
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Thirty percent of patched-1-heterozygous (Ptch 1/2 ) mice develop non-disseminated medulloblastoma by 8 months of age 5 . Recently, the Sleeping Beauty (SB) transposon system was shown to be an effective tool for functional genomics studies of solid tumour initiation and progression 6, 7 . We expressed the SB11 transposase in cerebellar progenitor cells in transgenic mice under the Math1 (also known as Atoh1) enhancer/promoter, but we did not observe any tumours when these mice were bred with mice transgenic for a concatemer of the T2/ Onc transposon 8 (Fig. 1a-j and Supplementary Figs 1 and 2) . However, on a Ptch 1/2 background, these Math1-SB11/T2Onc mice showed increased penetrance of medulloblastoma (,97%; 271 of 279 mice) compared with controls (,39%; 54 of 139 mice), as well as decreased latency (2.5 months compared with 8 months) ( Fig. 1 and Supplementary Fig. 2 ). Although Ptch 1/2 medulloblastomas are usually localized, the addition of SB transposition results in metastatic dissemination through the cerebrospinal fluid pathways, identical to the pattern that is seen in human children (Fisher's exact test, P 5 1.8 3 10 27 , odds ratio 5 5.2; Supplementary Table 1) ( Fig. 1c, d and Supplementary Fig. 2 ). As neither transposon nor transposase alone had an effect on tumour incidence, latency or dissemination, we conclude that SB-induced insertional mutagenesis drives medulloblastoma progression on the Ptch 1/2 background ( Fig. 1i and Supplementary Fig. 2 ).
Humans with germline mutations in the tumour-suppressor gene TP53 have Li-Fraumeni syndrome and have an increased risk of developing medulloblastoma. Although no medulloblastomas were found in mice with mutant Tp53 (also known as Trp53) (denoted Tp53 mut mice, which includes Tp53 1/2 and Tp53 2/2 ), 40% of Tp53 mut /Math1-SB11/T2Onc mice developed disseminated medulloblastoma 9 (Fig. 1e -h, j and Supplementary Fig. 2 ). Human medulloblastomas with TP53 mutations frequently have large cell/anaplastic histology. Tp53 mut /Math1-SB11/T2Onc medulloblastomas have large cells, nuclear atypia and nuclear moulding that is typical of large cell/ anaplastic histology ( Fig. 1f ). We conclude that SB transposition can drive the initiation and progression of metastatic medulloblastoma on a Tp53 mut background.
We used linker-mediated PCR and 454 sequencing to identify the site of T2/Onc insertions in Ptch 1/2 /Math1-SB11/T2Onc and Tp53 mut /Math1-SB11/T2Onc primary medulloblastomas and their matched metastases. Genes that contained insertions statistically more frequently than the background rate were identified as gene-centric common insertion sites (gCISs) 10 . We identified 359 gCISs in 139 primary tumours on the Ptch 1/2 background and 26 gCISs in 36 primary medulloblastomas on the Tp53 mut background ( Supplementary Tables 2-7 and Supplementary Figs 3 -5) . A large number of gCISs were candidate medulloblastoma oncogenes or tumour-suppressor genes 11 ( Supplementary Table 8 ). Insertions in candidate tumoursuppressor genes, including Ehmt1, Crebbp and Mxi1, are predicted to cause a loss of function ( Fig. 1k -m), whereas insertions in putative medulloblastoma oncogenes are largely gain of function, as exemplified by Myst3 ( Fig. 1n ).
Many gCISs mapped to regions of amplification, focal hemizygous deletion and homozygous deletion (Supplementary Table 8 ) that we recently reported in the genome of a large cohort of human medulloblastomas 11 . There is a high level of overlap between gCISs and known cancer genes (in the Catalogue of Somatic Mutations in Cancer (COSMIC) database) (Supplementary Tables 9 and 10), suggesting that many gCISs are bona fide driver genes in medulloblastoma (Fisher's exact test, P 5 0.0012) 12 . Similarly, many of the mouse gCISs and the genes amplified in human medulloblastomas are overexpressed in human SHH-driven medulloblastomas ( Supplementary  Fig. 6 ). Conversely, mouse gCISs hemizygously deleted in human medulloblastomas were frequently expressed at a lower level in human medulloblastomas ( Supplementary Fig. 6 ). The expression of six out of seven gCISs that had been studied by immunohistochemistry on a human medulloblastoma tissue microarray was associated with significantly worse overall and progression-free survival in human medulloblastoma 13 ( Supplementary Table 11 and Supplementary  Figs 7 and 8 ). We conclude that our SB-driven leptomeningealdisseminated medulloblastoma model resembles the human disease anatomically, pathologically and genetically and thus is an accurate model of the human disease that can be used to identify candidate driver events and understand the pathogenesis of human medulloblastoma.
We compared the gCISs identified from Ptch 1/2 /Math1-SB11/ T2Onc and Tp53 mut /Math1-SB11/T2Onc primary medulloblastomas and matched metastases (Supplementary Table 2 ). Strikingly, the overlap between primary tumour gCISs (pri-gCISs) from Ptch 1/2 /Math1-SB11/T2Onc tumours and those from metastases (met-gCISs) from the same animals was only 9.3% of all gCISs ( Fig. 2a) . Similarly, the overlap between pri-gCISs from Tp53 mut /Math1-SB11/T2Onc mice and the matching met-gCISs was only 8.9% (Fig. 2b ). The leptomeningeal metastases and the matched primary tumour have identical, highly clonal insertion sites on both genetic backgrounds (Fig. 2c ). The probability of two (or three) unrelated tumours having SB insertions in exactly the same TA dinucleotide is extremely low. We conclude that the leptomeningeal metastases and the matched primary tumour arise from a common transformed progenitor cell and have subsequently undergone genetic divergence.
Sequencing also identified insertions that are highly clonal in the metastases but are not observed in the matched primary tumour (data not shown). End-point PCR for these insertions in the matched primary and metastatic tumours shows that the insertion is highly clonal in the metastasis (or metastases) and is present in a very small subclone of the primary tumour ( Fig. 2d and Supplementary Fig. 9 ). These data are consistent with a model in which metastatic disease arises from a minor restricted subclone of the primary tumour. Dissemination could occur repeatedly from the same subclone of the primary tumour, which seeds the rest of the central nervous system, or it could occur once, followed by reseeding of the rest of the leptomeningeal space by the initial metastasis. Insertions that are restricted to a minor subclone of the 
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primary tumour but that are clonal in the metastases could correspond to the previously described 'metastasis virulence' genes 14 , which offer a genetic advantage during dissemination but not to the primary tumour. Another explanation for our data could be that the primary tumour was reseeded by a metastatic clone that had acquired additional genetic events in the periphery. This hypothesis is mitigated by the presence of highly clonal insertions in the metastasis that are completely absent from the primary tumour in the same animal 15 (Fig. 2e ).
As reseeding should be accompanied by contamination of the primary tumour with events found in the metastases, the absence of these events in the matched primary tumour makes reseeding much less likely ( Fig. 2e ). We propose that events found in only one metastasis represent progression events that are acquired post metastasis and that could lead to localized progression of metastatic disease, as is sometimes observed in human children.
We observed highly clonal insertions in the primary tumour, including in known medulloblastoma oncogenes such as Notch2 and Tert, that were not found in the matching metastases (Fig. 2f ). This pattern could be explained through remobilization of the SB transposon in the metastatic tumour; however, no signs of the DNA footprint remaining after SB remobilization at these loci were observed 16 ( Supplementary Fig. 10 ). We suggest that these events, which may constitute driver events in the primary tumour, have arisen in the primary tumour after the metastases have disseminated (post-dispersion events). Although these known oncogenes are attractive targets for therapy, their utility as targets may be limited if the targets are not also found in the leptomeningeal compartment of the disease. Our data from two separate mouse lines support a model in which medulloblastoma disseminates early from a restricted subclone of the primary tumour and in which the primary tumour and the matched metastases then undergo differential clonal selection and evolution. Failure to account for the differences between the primary and leptomeningeal compartments could lead to the failure of targeted therapies. Failure to study the leptomeningeal disease (Fig. 2d, e ) could result in systematically overlooking crucial targets for therapy in this compartment.
Examining the met-gCISs using Gene Set Enrichment Analysis (GSEA) demonstrated differences between the primary and metastatic disease, including enrichment for genes involved in the cytoskeleton in metastases ( Supplementary Table 12 ). Targets that are present in both compartments and are maintenance genes, as exemplified by Pdgfra, will be optimal targets for treating both the primary tumour and the metastases ( Fig. 2c and Supplementary Tables 7 and 9 ).
Pten, Akt2, Igf2 and Pik3r1 are all met-gCISs, implicating the phosphatidylinositol-3-OH kinase (PI(3)K) pathway in medulloblastoma progression. We injected the cerebellum of Nestin-TVA mice 17 with either an Shh-overexpressing retroviral vector (denoted Shh virus) or an Shh-and Akt-overexpressing retroviral vector (denoted Shh 1 Akt virus). Cerebellar injection of Shh virus alone resulted in medulloblastomas in 6 of 41 animals, compared with 20 of 42 animals injected with Shh 1 Akt virus (P 5 0.0018). Although metastases were not observed with Shh virus alone (0 of 41), medulloblastoma metastases were observed in 9 of 42 animals injected with Shh 1 Akt virus (P 5 0.0024) ( Supplementary Fig. 11 ). In vivo modelling validates PI(3)K signalling as a putative contributor to leptomeningeal dissemination of medulloblastoma.
Previous publications and clinical approaches to human medulloblastoma have largely assumed that the primary tumour and its matched metastases are highly similar 3, 4 . To test this assertion, we formally reviewed all cases of medulloblastoma from the past decade at The Hospital for Sick Children, in Ontario, Canada, and we identified 19 patients who had bulk residual primary tumour after surgery and metastases visible by magnetic resonance imaging, both of which could be followed for response to treatment ( Supplementary Fig. 12 and Supplementary Table 13 ). Although it is possible that the metastases received less radiotherapy than the primary tumour in a subset of patients, in 58% of all cases (11 of 19) we observed a disparate response to therapy between the primary tumour and the matched metastases (binomial test, P , 2.2 3 10 216 ). Identification of definitive differences in the clinical response to standard therapy between the primary and the metastatic compartment awaits the completion of large, well-controlled, prospective clinical trials.
We examined seven matched primary and metastatic medulloblastomas for copy number aberrations ( Fig. 3, Supplementary Figs 13 and  14 , and Supplementary Tables 14 and 15 ). In each case, the primary tumour and the matched metastases shared complicated genetic events that provide strong support for their descent from a common transformed progenitor cell. Similar to our mouse data, in each case we observed clonal genetic events in the metastatic tumour(s) that were not present in the matched primary tumour ( Fig. 3 and Supplementary  Fig. 14) . We also observed genetic events in the primary tumour that were absent from the matched metastases, consistent with a postdispersion event ( Fig. 3 and Supplementary Fig. 14) . One patient with multiple leptomeningeal metastases had a deletion of chromosome 1p in only one of three examined metastases (Fig. 3a) . This pattern of genetic events being present in only a subset of metastases could be a mechanism for the emergence of therapy-resistant metastatic clones.
We performed interphase fluorescence in situ hybridization (FISH) for the known medulloblastoma oncogenes MYCN and MYC on a collection of 17 paraffin-embedded primary and metastatic pairs of human medulloblastomas [18] [19] [20] . MYCN was amplified in three primary medulloblastomas but not in the matching metastases ( Fig. 3b and   a (13, 53 and 253, with the increase depicted by a wedge). Shown are clonal events found in both the primary tumour and matching metastases (met) (c), insertions that are highly clonal in the metastases but very subclonal in the matching primary tumour (d), insertions that are highly clonal in the metastases but undetectable in the matching primary tumour (e), and insertions that are highly clonal in the primary tumour but undetectable in the matching metastases (f). NC, negative control; genomic DNA from a Math1-SB11/T2Onc double-transgenic mouse cerebellum. Supplementary Fig. 15 ). Conversely, MYC was amplified in two primary tumours and their matching metastases (Fig. 3c ). These data are consistent with MYCN amplification being a post-dispersion event, similar to examples in SB-driven mouse medulloblastoma, and strongly indicate that anti-MYCN therapeutics may lack efficacy in the metastatic compartment of human medulloblastoma. The possibility that MYCN amplicons in the metastases have been 'lost' over time cannot be excluded.
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We subsequently analysed promoter CpG methylation in these matched pairs and found much discordance between the primary tumour and matched metastases ( Fig. 3d, Supplementary Figs 13  and 16 , and Supplementary Tables 16 and 17 ). Finally, we performed whole-exome sequencing on a limited set of matched primary and metastatic medulloblastomas and found many single nucleotide variants (SNVs) that were restricted to a single compartment (Supplementary Fig. 13 and Supplementary Table 18 ). The discordance of CNAs, promoter CpG methylation events and SNVs between the primary tumour and its matched metastases supports a bicompartmental model for metastatic medulloblastoma. The mutational load in the human tumours (the combination of CNAs, CpG methylation and SNVs) compares favourably with the mutational load in our transposondriven mouse models (in which the median number of gCISs is 25 per tumour; Supplementary Table 19 ). Validation of the individual CNAs that were restricted to the metastases showed that these CNAs can be detected in a very minor subclone of the primary tumour, in keeping with the relationship identified in the mouse model ( Supplementary  Fig. 17 and Supplementary Tables 20 and 21 ). Pathway analysis using the Database for Annotation, Visualization and Integrated Discovery (DAVID) to compare mouse gCISs with the genes that were affected in the human metastases identified only one statistically significant shared signalling pathway: insulin signalling (P 5 0.027) (Supplementary Table 22 ). The known role of insulin receptor signalling in primary medulloblastoma 21 , together with the data presented here on the role of AKT in metastatic medulloblastoma, suggests that insulin signalling should be prioritized as a therapeutic target to be tested in clinical trials.
We performed unsupervised hierarchical clustering on the CpG methylation data, and we found that normal cerebellar controls cluster away from the medulloblastomas, whereas metastases cluster with their matching primary tumour (Fig. 4a ). However, metastases cluster 
Adult-CB-5 Unsupervised hierarchical clustering by CpG methylation pattern demonstrates that patient-matched metastases are more similar to each other than to the matched primary tumour. b, Unsupervised clustering of regions of copy number gain and loss demonstrates that patient-matched metastases are more similar to each other than to the matched primary tumour. c, Unsupervised hierarchical clustering of SNV data from whole-exome sequencing demonstrates that patient-matched metastases are more similar to each other than to the matched primary tumour. SNVs that are found only in the primary compartment or only in both examined tumours in the metastatic compartment are evident. Coph, cophenetic correlation coefficient.
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closer to each other than they do to the matched primary tumour (z-test, P 5 0.0014) ( Supplementary Fig. 18 ). Unsupervised hierarchical clustering of CNA and exome SNV data uncovered the same relationships (Fig. 4b, c) . Evident within the exome data are many events that are shared only by patient-matched metastases (that is, metastases from a single patient), as well as events that are restricted to the primary tumour, both of which are similar to the genetic patterns observed in mice. These three data sets support a model in which patient-matched human medulloblastoma metastases are epigenetically and genetically very similar to each other but have substantially diverged from the primary tumour, resulting in two different disease compartments: the primary and metastatic compartments. Our data from two mouse models, with support from initial data from human medulloblastoma, suggest that leptomeningeal metastases of medulloblastoma from a single human or mouse are genetically similar to each other but are highly divergent from the matched primary tumour, consistent with a bicompartmental model of disease. Our results are consistent with a model in which metastases arise from a restricted subclone of the primary tumour through a process of clonal selection in both humans and mice. That metastases might arise from a pre-existing minor subclone of the primary tumour through clonal selection was suggested more than three decades ago, but it remains a controversial hypothesis that might not be true of all cancers [22] [23] [24] [25] . Failure to account for the divergent molecular pathology of the metastatic compartment may result in selection of therapeutic targets present in the primary tumour, which is more amenable to surgical control, but not the metastases, which are the more frequent cause of death.
METHODS SUMMARY
Generation of Math1-SB11 construct. SB11 cDNA was excised from the vector pCMV-SB11 and ligated into the vector J2Q-Math1 (refs 8, 26) . Linker-mediated PCR and 454 deep sequencing. Bar-coded, linker-mediated PCR was performed as previously described 6 . Sample preparation for the 454 sequencing and the subsequent procedures was performed as previously described 27 . Determination of gCISs. A chi-squared analysis was performed to determine whether the number of observed integration events within each transcription unit in the SB-driven medulloblastomas was significantly greater than expected given the following: the number of TA dinucleotide sites within the gene relative to the number of TA sites in the genome, the number of integration sites within each tumour, and the total number of tumours in each cohort. This gCIS analysis produced a P value for each of the ,19,000 mouse RefSeq genes, and Bonferroni correction was therefore used to adjust for multiple hypothesis testing.
